SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The mission of the Worldcoin project is to build the world’s largest identity and financial network as a public utility, giving ownership to everyone. A key component of the Worldcoin project is the development of the foundational infrastructure that will be important for a world where AI plays an increasingly large role.  The Worldcoin system revolves around World ID, a privacy-preserving global identity network. World ID enables users to verify their humanness online while maintaining their privacy through zero-knowledge proofs.  Using World ID, individuals will be able to prove that they are a real, unique human to any platform that integrates with the protocol, including to web3 systems, social networking sites, and governmental programs. This will enable fair airdrops or token/NFT sales, provide protection against bots/sybil attacks on social media, and enable the fairer distribution of limited governmental resources. Furthermore, World ID can also enable global democratic processes and novel forms of governance (e.g., via quadratic voting), and it may eventually show a path to AI-funded UBI. The Worldcoin token (WLD), alongside World ID, will let users participate in governing the Worldcoin protocol.   To engage with the Worldcoin protocol, individuals must first download a first wallet app that supports the creation of a World ID. Users visit a physical imaging device called the Orb to get their World ID Orb-verified. Orbs are operated by a network of independent local businesses called Orb Operators. The Orb uses multispectral sensors to verify humanness and uniqueness to issue an Orb-verified World ID, with all images being promptly deleted on-device per default (absent explicit consent to Data Custody). All Orb-verified World IDs holders are entitled to claim recurring grants of free WLD tokens, subject to certain availability restrictions. The WLD token is designed as a utility token with governance properties.

Worldcoin

Worldcoins rally through the $0.60 level and technical breakout are drawing attention, with traders also pointing to Eightco/ORBSs reported large WLD holdings as a potential source of support. Sentiment is largely bullish, though some caution the move may be crowded and remain volatile.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as smartphones, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

TSMs push toward recent highs is drawing bullish attention, with traders citing sustained AI-chip demand, tight foundry capacity and heavy call activity; reports that the company is considering a Texas campus add to the discussion but remain unconfirmed. Some traders are skeptical of the rally and are positioning for a pullback.

Lam Research Corp. engages in the design, manufacture, marketing, refurbishment, and provision of semiconductor processing equipment used in the fabrication of integrated circuits. It operates through the following geographical segments: United States, China, Europe, Japan, Korea, Southeast Asia, and Taiwan. The company was founded by David K. Lam in 1980 and is headquartered in Fremont, CA.

Lam Research Corp.

Lam Research is drawing attention as traders connect AI-driven semiconductor investment and rising memory-fab spending to demand for its manufacturing equipment, with Microns capex and backlog serving as a positive read-through. Analyst optimism and breakout talk are offset by caution about resistance, valuation, and the sectors volatility.

Pump.fun

PUMP is drawing attention around a possible rebound, with traders pointing to improving price action and Pump.funs revenue and token buybacks as bullish support. Others remain skeptical, citing the tokens selloffs and questioning whether the momentum can hold.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disneys quarterly earnings beat, led by strength in parks and improving streaming performance, has drawn attention, alongside a higher share-repurchase plan. Bulls see evidence of improving execution, while skeptics point to slightly softer revenue and the stocks history of muted follow-through.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

Strong quarterly results and a DaVita DefenCath agreement and pilot have drawn attention, though traders are frustrated that the shares did not hold their gains. Debate centers on whether adoption can offset post-TDAPA reimbursement pressure, with Medicare Advantage coverage and new real-world evidence seen as potential support for longer-term demand.

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

Natera Inc

Repeated 52-week highs and a powerful run are driving attention, with bullish traders citing strong results and demand for Nateras MRD testing while skeptics warn the valuation is stretched and the rally may be hard to sustain.

American Bitcoin Corp. engages in the management of a bitcoin accumulation platform. It offers exposure to bitcoin through an industry-first business model that integrates scaled self-mining operations with disciplined accumulation strategies. The company was founded by Eric Trump and Donald John Trump Jr. on October 3, 2018 and is headquartered in Miami, FL.

American Bitcoin Corp. - Ordinary Shares - Class A

American Bitcoin Corp.

ABTC is drawing attention as traders link its swings to Bitcoins price and speculate that heavy short positioning could amplify a rebound. Bulls point to its Bitcoin holdings and mining growth, while skeptics focus on dilution, reverse splits, and the stocks severe losses.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

ABVX is drawing attention as shares continue to slide despite bullish views of obefazimods ulcerative-colitis data, with traders debating whether a takeover will materialize or the stock will languish until regulatory and Crohns-disease milestones. Buyout speculation remains unconfirmed, while concerns about the wait for catalysts and persistent selling fuel bearish frustration.

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

JDs planned Ceconomy acquisition and the anticipated European Commission decision are a near-term focus, with traders expecting approval but awaiting the final ruling. The broader discussion remains divided between value-focused buyers and frustrated holders concerned by JDs persistent weakness and China-market headwinds.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buy

Minerva Neurosciences (NERV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Minerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Minerva Neurosciences (NERV) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Minerva Neurosciences (NASDAQ:NERV) Posts Quarterly Earnings Results, Misses Expectations By $0.04 EPS

Minerva Neurosciences (NASDAQ:NERV - Get Free Report) released its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing...

Minerva Neurosciences, Inc (NASDAQ:NERV) Short Interest Update

Minerva Neurosciences, Inc (NASDAQ:NERV - Get Free Report) was the target of a significant increase in short interest during the month of April. As of April 15th, there was short interest totaling...

Minerva Neurosciences (NASDAQ:NERV) Now Covered by Citizens Jmp

Citizens Jmp began coverage on Minerva Neurosciences in a report on Wednesday. They set an "outperform" rating and a $14.00 target price for the company...

Minerva Neurosciences, Inc (NASDAQ:NERV) Sees Significant Growth in Short Interest

Minerva Neurosciences, Inc (NASDAQ:NERV - Get Free Report) was the target of a large increase in short interest in the month of March. As of March 31st, there was short interest totaling 1,020,925...

Minerva Neurosciences (NASDAQ:NERV) Shares Cross Below Fifty Day Moving Average - Should You Sell?

Minerva Neurosciences (NASDAQ:NERV) Stock Passes Below Fifty Day Moving Average - Here's What Happened...

Short Interest in Minerva Neurosciences, Inc (NASDAQ:NERV) Grows By 27.8%

Minerva Neurosciences, Inc (NASDAQ:NERV - Get Free Report) saw a significant growth in short interest in March. As of March 13th, there was short interest totaling 559,530 shares, a growth of 27.8...

Minerva Neurosciences Touts Roluperidone Data, FDA-Aligned Trial Plan for Schizophrenia Symptoms

Minerva Neurosciences (NASDAQ:NERV) provided an update on its development program for roluperidone, which the company described as a potential first treatment option aimed at the negative symptoms of...

HC Wainwright Has Bullish Forecast for NERV Q1 Earnings

Minerva Neurosciences, Inc (NASDAQ:NERV - Free Report) - Equities research analysts at HC Wainwright increased their Q1 2026 earnings per share (EPS) estimates for shares of Minerva Neurosciences in...

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.

Minerva Neurosciences Inc

Minerva Neurosciences Stock Hits Near 2-Year High On FDA Pathway, $200M Boost — Retail Sees FDA Catalyst

Equity

Bullish Sentiment

Up more than 5%

Flat to up 5%

Flat to down 5%

Down more than 5%

What&#39;s your expected total return for the S&amp;P 500 ($SPY) in Q4? 

Drop your reasoning in the comments.

Stocktwits

What's your expected total return for the S&P 500 (

) in Q4? 

Drop your reasoning in the comments.

Current Price	$3.28
Prev Close	$3.23
Open	$3.29
Dividend Yield	0.00%
50-Day Moving Average	$4.16
Beta	0.92
Avg. Volume	158,076.45
PE Ratio	-0.11

52-Week High	$12.46
52-Week Low	$2.08
Market Capitalization	$156.61M
EPS (Annual)	-$34.67
Price to Book	-0.73
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

NERV Fundamentals